Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2025
0mins
Source: Businesswire
Candid Therapeutics and WuXi Biologics Agreement: Candid Therapeutics has secured exclusive global rights to a preclinical trispecific T-cell Engager from WuXi Biologics, aiming to advance its T-cell engagers for autoimmune diseases and plans to initiate first-in-human studies by mid-2026.
Financial Terms of the Collaboration: The agreement includes an upfront payment and potential milestones totaling up to $925 million for WuXi Biologics, highlighting their role as a key partner in developing next-generation therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
